KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Non-Current Deffered Revenue (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $170.0 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Non-Current Deffered Revenue rose 709.54% year-over-year to $170.0 million, compared with a TTM value of $170.0 million through Sep 2023, up 709.54%, and an annual FY2022 reading of $174.8 million, up 12.04% over the prior year.
  • Non-Current Deffered Revenue was $170.0 million for Q3 2023 at Ginkgo Bioworks Holdings, down from $179.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $179.9 million in Q2 2023 and bottomed at $12.7 million in Q4 2020.
  • Average Non-Current Deffered Revenue over 4 years is $95.1 million, with a median of $60.4 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 1130.41% in 2021, then tumbled 68.1% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $12.7 million in 2020, then surged by 1130.41% to $156.0 million in 2021, then grew by 12.04% to $174.8 million in 2022, then decreased by 2.72% to $170.0 million in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for DNA at $170.0 million in Q3 2023, $179.9 million in Q2 2023, and $174.8 million in Q1 2023.